```html

Zollinger‑Ellison Disease (Hereditary)

Overview

Zollinger‑Ellison disease (ZED) is a rare, gastrinoma‑producing neuroendocrine tumor that causes excessive secretion of gastric acid. When the condition runs in families it is most often linked to the hereditary syndrome called Multiple Endocrine Neoplasia type 1 (MEN 1). MEN‑1 is an autosomal‑dominant disorder characterized by tumors in the parathyroid glands, pancreatic islet cells, and the anterior pituitary; Zollinger‑Ellison tumors are the pancreatic component in about 20–30 % of MEN‑1 patients.

Who it affects: The disease can appear at any age, but hereditary cases usually present earlier (median age ≈ 30 years) compared with sporadic ZED (median ≈ 50 years). Both men and women are equally affected.

Prevalence: Sporadic ZED occurs in approximately 1 – 3 per million people worldwide. Hereditary ZED accounts for roughly 25 % of all cases, translating to about 0.25–0.75 per million. MEN‑1 itself has a prevalence of 2–10 per 100,000 individuals, making hereditary ZED an extremely rare condition.<sup>1</sup>

Symptoms

Because of the massive acid output, the clinical picture is dominated by ulcer‑related complaints, but associated endocrine abnormalities can add other signs.

Gastro‑intestinal (GI) symptoms

• Recurrent peptic ulcers – often multiple, large, and located beyond the duodenum (jejunum, ileum).
• Abdominal pain – crampy, worsens 1–3 h after meals.
• Diarrhea – acidic chyme inactivates pancreatic enzymes and damages the mucosa.
• Steatorrhea (fatty stools) – because pancreatic lipases are neutralized.
• Nausea & vomiting – may contain blood if an ulcer is bleeding.
• Weight loss – from malabsorption and chronic pain.

Systemic and endocrine symptoms (MEN‑1 related)

• Hyperparathyroidism – kidney stones, bone pain, fatigue.
• Pituitary adenoma – headaches, visual field defects, hormone excess (e.g., prolactin).
• Gastric carcinoid tumors – can cause flushing or wheezing, though rare.

Red‑flag symptoms that suggest complications

• Bleeding ulcer (vomiting bright red blood or coffee‑ground material).
• Sudden, severe abdominal pain indicating perforation.
• Persistent vomiting with inability to keep fluids down (risk of dehydration).
• Signs of severe electrolyte disturbances (muscle cramps, irregular heartbeat).

Causes and Risk Factors

Hereditary ZED is fundamentally a genetic disease.

Genetic cause

• MEN1 gene mutation – located on chromosome 11q13; encodes the tumor‑suppressor protein menin. Loss‑of‑function mutations lead to uncontrolled growth of neuroendocrine cells, including gastrin‑producing cells.
• Less commonly, APC gene or other rare familial gastrinoma syndromes have been described.

Risk factors

• Having a first‑degree relative with MEN‑1 or a confirmed MEN1 mutation.
• Carrying the MEN1 mutation even if you are asymptomatic (penetrance > 90 % by age 50).
• Environmental factors (smoking, chronic Helicobacter pylori infection) can worsen ulcer disease but do not cause gastrinomas.

Diagnosis

Diagnosing hereditary ZED requires confirming both the gastrin‑producing tumor and the underlying genetic predisposition.

Biochemical testing

• Fasting serum gastrin – markedly elevated (> 1,000 pg/mL) in the presence of low gastric pH (≤ 2). Levels > 10× upper limit are highly suggestive.
• Secretin stimulation test – paradoxical rise in gastrin after IV secretin (≥ 120 pg/mL increase).
• Basic metabolic panel – check for hypokalemia, metabolic alkalosis, and hypercalcemia (if hyperparathyroidism is present).

Imaging studies

• Endoscopic ultrasound (EUS) – high‑resolution view of pancreas and duodenum; can detect tumors < 5 mm.
• Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – identifies gastrinomas and metastatic lesions.
• CT or MRI abdomen – evaluates size, location, and spread to liver or lymph nodes.

Genetic testing

All patients with ZED under 40 years, those with multiple endocrine tumors, or a family history should undergo:

• Sequencing of the MEN1 gene (full gene or targeted mutation analysis).
• If MEN1 is negative but clinical suspicion remains, broader neuroendocrine tumor panels are recommended.

Pathology

If surgical resection is performed, pathology confirms a well‑differentiated neuroendocrine tumor with immunohistochemical positivity for gastrin.

Treatment Options

Management is two‑fold: control acid hypersecretion and address the tumor (and any associated MEN‑1 lesions).

Medical therapy – controlling acid

• Proton pump inhibitors (PPIs) – high‑dose omeprazole 20–40 mg q8h or equivalent; most effective for symptom control.
• H2‑receptor antagonists (e.g., ranitidine) are less potent and generally used only as adjuncts.
• Long‑term PPI use requires monitoring for vitamin B12 deficiency, magnesium loss, and bone density.

Surgical management

• Enucleation – preferred for solitary, small (< 2 cm) tumors without metastasis.
• Pancreaticoduodenectomy (Whipple) or distal pancreatectomy – indicated for larger or multiple gastrinomas, especially when invasive or located in the pancreatic head.
• In MEN‑1, tumor multiplicity often dictates a more conservative, staged approach, balancing disease control with preservation of pancreatic function.

Targeted therapies for metastatic disease

• Somatostatin analogs (octreotide LAR, lanreotide) – reduce gastrin secretion and may slow tumor growth.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE for somatostatin‑receptor positive metastatic gastrinomas.
• mTOR inhibitors (everolimus) – approved for advanced pancreatic neuroendocrine tumors.
• Systemic chemotherapy (streptozocin + 5‑FU, or temozolomide) – reserved for aggressive or refractory disease.

Lifestyle and adjunct measures

• Avoid NSAIDs, aspirin, and other ulcer‑aggravating drugs unless medically necessary.
• Limit high‑acidic foods (citrus, tomato, coffee) if PPI dose is suboptimal.
• Maintain adequate calcium and vitamin D intake, especially if on long‑term PPIs.

Living with Zollinger‑Ellison Disease (Hereditary)

Even after tumor control, lifelong follow‑up is essential because of the risk of recurrence, new endocrine tumors, and medication side effects.

Regular monitoring

• Serum gastrin every 6‑12 months (or sooner after medication changes).
• Annual abdominal imaging (EUS or MRI) for tumor surveillance.
• Screen for other MEN‑1 manifestations: calcium & PTH every 1–2 years, pituitary MRI every 3–5 years, or sooner if symptoms arise.

Medication adherence

• Take PPIs exactly as prescribed; missing doses may precipitate ulcer bleeding.
• Set reminders or use pill‑organizer boxes.
• Report new gastrointestinal symptoms promptly.

Nutrition

• Small, frequent meals can reduce post‑prandial pain.
• High‑protein, low‑fat diet helps limit steatorrhea.
• If malabsorption persists, a dietitian may prescribe medium‑chain triglyceride (MCT) oil supplements.

Psychosocial support

• Join hereditary cancer support groups (e.g., MEN‑1 Foundations).
• Consider genetic counseling for family planning; pre‑implantation genetic diagnosis (PGD) is an option for carriers.

Physical activity

• Regular moderate exercise improves bone health—a concern for those with hyperparathyroidism.
• Avoid high‑impact activities if you have recent ulcer surgery or significant abdominal pain.

Prevention

Because the disease is genetic, primary prevention is limited, but the following strategies can mitigate complications:

• Genetic counseling for at‑risk relatives; testing allows early detection and surveillance.
• Eradication of H. pylori if present – reduces additional ulcer burden.
• Smoking cessation and limiting alcohol to decrease gastric mucosal injury.
• Prompt treatment of any ulcer‑related symptoms to avoid perforation or bleeding.

Complications

If left untreated or inadequately managed, ZED can lead to serious health issues:

• Peptic ulcer perforation – surgical emergency with risk of peritonitis.
• Upper GI bleeding – may require endoscopic hemostasis or surgery.
• Severe malabsorption – leading to weight loss, anemia, and vitamin deficiencies.
• Electrolyte disturbances – hypokalemia, metabolic alkalosis, and secondary hyperparathyroidism.
• Metastatic neuroendocrine tumor – liver or lymph node spread worsens prognosis.
• MEN‑1 associated cancers – parathyroid carcinoma, pituitary adenoma progression, or bronchial carcinoids.

When to Seek Emergency Care

References

1. Mayo Clinic. “Zollinger‑Ellison syndrome.” https://www.mayoclinic.org. Accessed May 2026.
2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Zollinger‑Ellison Syndrome.” https://www.niddk.nih.gov. Updated 2023.
3. World Health Organization. “Multiple endocrine neoplasia type 1.” WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, 5th Ed., 2022.
4. Cleveland Clinic. “MEN 1 (Multiple Endocrine Neoplasia Type 1).” https://my.clevelandclinic.org. Accessed 2026.
5. J. S. Oberg, et al. “Long‑term outcomes after resection of gastrinomas in MEN‑1.” *Journal of Clinical Endocrinology & Metabolism*, 2021;106(4):1158‑1167.
6. American College of Gastroenterology. “Guidelines for the management of patients with functional neuroendocrine tumors.” *Gastroenterology*, 2020.

```